clinical trial · NCT05797831
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
Kartos Therapeutics, Inc.·phase3·recruiting·n = 268
Endometrial CancerNavtemadlinNavtemadlin Placebo
brief summary
This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have achieved complete response or partial response on chemotherapy. The study will be conducted in 2 parts. Part 1 will evaluate safety and efficacy of two different doses of navtemadlin alongside an observational control arm to determine the Phase 3 navtemadlin dose. Part 2 will evaluate the efficacy and safety of navtemadlin Phase 3 dose compared to placebo.
started
Jul 17, 2023
primary completion
Aug 1, 2025
completion
Jul 1, 2027
last updated
May 2, 2024
official title
A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects With TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol